Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
November 22 2024 - 7:00AM
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live
biotherapeutics company, today announced that Eric Shaff, President
and Chief Executive Officer, will participate in a fireside chat at
the Piper Sandler 36th Annual Healthcare Conference on December 3,
2024, at 4:30 p.m. ET.
A live webcast of the chat will be accessible through the
“Events and Presentations” tab on the “Investors and News” section
of the Company’s website at www.serestherapeutics.com and will be
available for replay following the event.
About Seres TherapeuticsSeres
Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company
focused on improving patient outcomes in medically vulnerable
populations through novel live biotherapeutics. Seres led the
successful development and approval of VOWST™, the first
FDA-approved orally administered microbiome therapeutic, and which
was sold to Nestlé Health Science in September 2024. The
Company is developing SER-155, which has demonstrated a significant
reduction in bloodstream infections and related complications
(as compared to placebo) in a clinical study in patients undergoing
allogeneic hematopoietic stem cell transplantation (allo-HSCT).
SER-155 and the Company's other pipeline programs are designed to
target multiple disease-relevant pathways and are manufactured from
standard clonal cell banks via cultivation, rather than from the
donor-sourced production process used for VOWST. In addition to
allo-HSCT, the Company intends to evaluate SER-155 and other
cultivated live biotherapeutic candidates in other medically
vulnerable patient populations, including autologous-HSCT patients,
cancer patients with neutropenia, CAR-T recipients, individuals
with chronic liver disease, solid organ transplant recipients, as
well as patients in the intensive care unit and long-term acute
care facilities. For more information, please
visit www.serestherapeutics.com.
Investor and Media
Contacts:IR@serestherapeutics.com
Carlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
This press release was published by a CLEAR® Verified
individual.
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Oct 2024 to Nov 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Nov 2023 to Nov 2024